Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia (AML) After Allogeneic Stem Cell Transplantation

Trial Profile

Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia (AML) After Allogeneic Stem Cell Transplantation

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2018

At a glance

  • Drugs Decitabine (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Aug 2016 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
    • 29 Aug 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
    • 18 Feb 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top